Investing.comDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 19:36:31·⟳ 抓取 19:37:15 +44s·⚡ 决策 10-20 19:40:48 +3m33s·7.0 天前
Actinium在EANM公布ATNM-400肺癌/结直肠癌/卵巢癌临床前数据，但属已预期会议的增量临床前结果且股价周一已大涨
这是已预告学术会议上的临床前（动物模型）数据，不构成临床/监管状态迁移，pan-tumor数据此前已在AACR（2026-04）、SNMMI（2026-06）展示；公司10月15日预告、10月19日发稿，ATNM周一已放量大涨16.81%（量比5.83），Investing.com 10月20日的报道只是通稿改写，剩余edge不足以追多；亦无任何利空可做空。
📄 原文Investing.com↗ 原文
Actinium presents preclinical data on ATNM-400 cancer treatment
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) presented preclinical data on Monday showing activity of…
不做 Actinium Pharmaceuticals, Inc.（ATNM.US）
已price-in且催化偏弱：EANM演讲10月15日预告、10月19日公司发稿，周一ATNM已放量+16.81%（5日+24.5%）；新增的肺癌/结直肠癌/卵巢癌结果全部为临床前模型TGI，不改变I期临床状态、无法量化业绩增量，Investing.com文章仅为通稿改写。盘前价差约7%、成交极薄，追多无edge；也无实质利空支持做空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ATNM-400新增肺癌/结直肠癌/卵巢癌数据仍停留在临床前阶段，距收入兑现需多年且无法量化，EANM演讲早于10月15日预告、10月19日发稿，股价周一已放量上涨16.81%，消息基本price-in，不追多也不做空。
消息传播链
- 节点
- 节点
- 节点
关键理由
- 若交易，唯一多头逻辑是pan-tumor临床前数据强化平台想象空间，但该主题年内已多次披露且本次无人体疗效新数据
- 市值仅约4150万美元的微盘股对管线消息敏感，然而周一16.81%的放量上涨已反映本次EANM催化
主要风险
- 微盘股买卖价差大（1.30/1.39）、盘前流动性极差（仅174股），追高易被套在情绪高点
- 临床前TGI不能外推人体疗效，ATNM-400仅前列腺癌处于I期，存在安全性/有效性证伪风险
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
未发现本次事件相关的新安全性/临床利空；但公司为持续亏损的微盘临床期公司（PE为负），ATNM-400仅I期，临床前数据不验证人体疗效，弱基本面与早期阶段构成多头反证
检索:ATNM-400 clinical trial phase setbacks Actinium cash runway dilution 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:因判定已price-in且临床前数据无财务量级，直接AVOID，先例不构成做或不做的边际依据
方向:未做外部先例量化：本催化为已预告学术会议的临床前数据，且周一价格已明确完成重定价，方向与幅度证据不改变结论
涨幅量级:不足：无可对齐的同主体、同相位首发先例（本次首发锚点为10-15/10-19公司IR，而非Investing转载）
形态:微盘生物科技股在已预告的学术会议后常见借利好派发，但未用先例统计定tp/sl
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`actinium pharmaceuticals atnm-400 preclinical data eanm 2026 her3 | actinium pharmaceuticals eanm vienna congress presentation october 2026 | atnm-400 actinium-225 alpha radioconju`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 1,014 ms
{ - web_search 成功 doubao_search · 1,800 ms
豆包搜索结果（原始查询:Actinium ATNM-400 EANM 2026 preclinical HER3 data abstract；API SearchType:web）
原文全文
展开原文 · 1,745 字
NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) presented preclinical data on Monday showing activity of its experimental cancer treatment ATNM-400 across lung, colorectal and ovarian cancer models at the 39th Annual Congress of the European Association of Nuclear Medicine in Vienna, Austria.
ATNM-400 is an antibody radioconjugate that targets HER3, a protein associated with cancer cell survival and treatment resistance. The drug delivers alpha-particle radiation using Actinium-225.
In non-small cell lung cancer models, ATNM-400 showed activity across tumors driven by different genetic mutations including EGFR, KRAS and ALK. In a KRAS G12C-mutant model, ATNM-400 achieved 81% tumor growth inhibition as a single agent. When combined with adagrasib, tumor growth inhibition increased to 105%.
In colorectal cancer, ATNM-400 combined with oxaliplatin and bevacizumab achieved 72% tumor growth inhibition in a model with moderate HER3 expression, compared with 25% for oxaliplatin and bevacizumab alone, according to the company’s statement.
In ovarian cancer models, ATNM-400 as a single agent achieved 93% tumor growth inhibition, compared with 54% for bevacizumab. The drug retained activity following bevacizumab failure, achieving 50% tumor growth inhibition.
The company is currently conducting a Phase 1 clinical trial of ATNM-400 in metastatic castration-resistant prostate cancer. The preclinical studies presented at EANM evaluated the drug in additional cancer types.
The information is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Actinium presents preclinical data on ATNM-400 cancer treatment
ATNM-400 is an antibody radioconjugate that targets HER3, a protein associated with cancer cell survival and treatment resistance. The drug delivers alpha-particle radiation using Actinium-225.
In non-small cell lung cancer models, ATNM-400 showed activity across tumors driven by different genetic mutations including EGFR, KRAS and ALK. In a KRAS G12C-mutant model, ATNM-400 achieved 81% tumor growth inhibition as a single agent. When combined with adagrasib, tumor growth inhibition increased to 105%.
In colorectal cancer, ATNM-400 combined with oxaliplatin and bevacizumab achieved 72% tumor growth inhibition in a model with moderate HER3 expression, compared with 25% for oxaliplatin and bevacizumab alone, according to the company’s statement.
In ovarian cancer models, ATNM-400 as a single agent achieved 93% tumor growth inhibition, compared with 54% for bevacizumab. The drug retained activity following bevacizumab failure, achieving 50% tumor growth inhibition.
The company is currently conducting a Phase 1 clinical trial of ATNM-400 in metastatic castration-resistant prostate cancer. The preclinical studies presented at EANM evaluated the drug in additional cancer types.
The information is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Actinium presents preclinical data on ATNM-400 cancer treatment
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
f53ee12773· 2026-10-20 19:40 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前